Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2086 Multiple Ascending Dose and Food Effect Study in Healthy Adults
NCT06481488Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of E2086 in narcolepsy (5 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Treatment-emergent Adverse Events at Day 10, Serious Adverse Events at Day 10 and 5 more. Started Jun 2024; status: completed.
02
Drugs
E2086
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT06481488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06481488.